Syngene International cash flow

Latest FY26

Cash from operations: ₹915cr−21.6% on FY25
Capital spending: ₹368cr−52.2% on FY25
Free cash flow: ₹547cr+37.6% on FY25
Cash from financing: −₹215cr−₹142 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	453	433	426	367
	—	0.0	53.1	45.1	34.5
	—	0.0	−55.9	−60.3	−60.4
	—	41.3	37.3	0.5	23.6
	—	3.7	0.0	−3.6	24.5
	—	0.0	3.8	8.0	−3.1
	—	0.0	0.0	−36.1	−0.7
	—	14.2	74.3	115	−153
	—	−19.9	−93.9	86.7	6.9
	—	0.0	0.0	−14.4	−117
	—	0.0	−22.7	0.0	35.7
	—	−146	0.0	192	8.6
	—	0.0	10.1	−109	−1.4
	—	221	90.7	−3.1	24.7
	—	0.0	0.0	−35.6	19.6
	—	0.0	0.0	−21.5	13.1
	—	0.0	109	−45.8	133
	—	0.0	−15.5	−12.8	3.6
	—	28.3	0.0	19.2	−1.2
	—	0.0	0.0	−3.0	9.3
Cash from operating activities
	252	411	660	621	594
	—	596	623	546	367
	—	1,006	1,283	1,167	960
	—	48.8	0.0	0.0	0.0
	—	60.2	0.0	0.0	0.0
	—	−10.5	0.0	0.0	0.0
	—	69.3	115	125	137
	—	915	1,168	1,042	824
Cash from investing activities
	—	344	760	492	507
	—	24.2	9.8	18.8	11.7
	—	0.0	0.0	22.1	0.0
	—	3.5	0.0	0.0	2.9
	—	0.0	0.0	553	18.2
	—	50.8	50.3	81.5	54.0
	—	−540	−24.9	465	−171
	—	−860	−745	−496	−656
Cash from financing activities
	—	0.4	0.5	0.0	0.0
	—	0.0	17.1	0.0	0.0
	—	99.6	41.7	436	258
	—	54.8	53.6	36.7	9.8
	—	10.6	13.8	28.8	34.5
	—	50.4	50.3	50.3	40.1
	—	−215	−142	−551	−343
	—	−160	281	−4.9	−175
	—	21.7	0.3	1.1	3.1
	—	−139	281	−3.8	−172
	—	—	—	85.7	89.5
Reference items
	751	919	1,042	1,014	934
	21.3%	24.6%	28.6%	29.1%	29.3%
	547	547	398	531	305
	—	426	362	68.9	—
	₹13.58	₹13.58	₹9.87	₹13.19	₹7.58
	29.36×	—	—	—	—
	—	2.89×	2.35×	2.04×	1.77×
	—	69.3	115	125	137
	—	10.6	13.8	28.8	34.5

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SYNGENE₹398.60

Syngene International Ltd.

· Pharma & Health

₹ CrorePeersSAILIFE DIVISLAB WOCKPHARMA GLAND ASTERDM PPLPHARMA COHANCE LALPATHLABMcap ₹16,060 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	366.5	425.9	432.6	452.9	—
+ Finance Costs	34.5	45.1	53.1	0.0	—
+ Interest Income	-60.4	-60.3	-55.9	0.0	—
+ Share-based Payments	23.6	0.5	37.3	41.3	—
+ Unrealised FX (Gain) / Loss	24.5	-3.6	0.0	3.7	—
+ Other Non-cash Items	-3.1	8.0	3.8	0.0	—
+ Other Reconciling Items	-0.7	-36.1	0.0	0.0	—
Changes in Working Capital
+ Inventories	-153.4	114.6	74.3	14.2	—
+ Trade Receivables — Current	6.9	86.7	-93.9	-19.9	—
+ Other Financial Assets — Current	-116.8	-14.4	0.0	0.0	—
+ Other Financial Assets — Non-current	35.7	0.0	-22.7	0.0	—
+ Other Current Assets	8.6	192.0	0.0	-146.1	—
+ Other Non-current Assets	-1.4	-109.4	10.1	0.0	—
+ Trade Payables — Current	24.7	-3.1	90.7	221.1	—
+ Other Financial Liabilities — Current	19.6	-35.6	0.0	0.0	—
+ Other Financial Liabilities — Non-current	13.1	-21.5	0.0	0.0	—
+ Other Current Liabilities	133.1	-45.8	109.1	0.0	—
+ Other Non-current Liabilities	3.6	-12.8	-15.5	0.0	—
+ Provisions — Current	-1.2	19.2	0.0	28.3	—
+ Provisions — Non-current	9.3	-3.0	0.0	0.0	—
Cash from Operating Activities
Profit Before Tax (per I/S)	593.6	620.8	659.9	410.9	252.2
+ Total Adjustments (incl. Working Capital)	366.7	546.4	623.0	595.5	—
Cash from Operations (pre-tax)	960.3	1,167.2	1,282.9	1,006.4	—
+ Interest Received — Operating	0.0	0.0	0.0	48.8	—
+ Interest Paid — Operating	0.0	0.0	0.0	60.2	—
+ Other Inflows / (Outflows) — Operating	0.0	0.0	0.0	-10.5	—
+ Income Taxes Paid	136.8	125.1	115.3	69.3	—
Cash from Operating Activities	823.5	1,042.1	1,167.6	915.2	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	506.6	492.0	760.3	344.0	—
+ Acq of Intangible Assets	11.7	18.8	9.8	24.2	—
+ Disp of Other Long-term Assets	0.0	22.1	0.0	0.0	—
+ Purchase of Investments (Equity / Debt)	2.9	0.0	0.0	3.5	—
+ Acq of Subsidiaries / Businesses (net)	18.2	553.2	0.0	0.0	—
+ Interest Received — Investing	54.0	81.5	50.3	50.8	—
+ Other Inflows / (Outflows) — Investing	-171.0	464.8	-24.9	-539.5	—
Cash from Investing Activities	-656.4	-495.6	-744.7	-860.4	—
Cash from Financing Activities
+ Proceeds from Issue of Shares	0.0	0.0	0.5	0.4	—
+ Proceeds from Borrowings	0.0	0.0	17.1	0.0	—
+ Repayment of Borrowings	258.1	435.6	41.7	99.6	—
+ Payment of Lease Liabilities	9.8	36.7	53.6	54.8	—
+ Interest Paid	34.5	28.8	13.8	10.6	—
+ Dividends Paid	40.1	50.3	50.3	50.4	—
Cash from Financing Activities	-342.5	-551.4	-141.8	-215.0	—
Net Changes in Cash (pre-FX)	-175.4	-4.9	281.1	-160.2	—
+ Effect of FX Rate Changes on Cash	3.1	1.1	0.3	21.7	—
Net Changes in Cash	-172.3	-3.8	281.4	-138.5	—
Closing Cash	89.5	85.7	—	—	—
Reference Items
EBITDA	934.4	1,014.4	1,041.8	918.5	750.8
EBITDA Margin %	29.26	29.08	28.60	24.57	21.32
Free Cash Flow (CFO − Capex)	305.2	531.3	397.5	547.0	547.0
Free Cash Flow to Equity	—	68.9	361.6	426.2	—
Free Cash Flow per Basic Share	7.58	13.19	9.87	13.58	13.58
Price to Free Cash Flow	—	—	—	—	29.36
Cash Flow to Net Income	1.77	2.04	2.35	2.89	—
Cash Paid for Taxes	136.8	125.1	115.3	69.3	—
Cash Paid for Interest	34.5	28.8	13.8	10.6	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.